The bill is bogged down in the Senate over how high damages for patent infringement should be and other sticking points.
WASHINGTON
(Reuters) - A long-negotiated patent overhaul bill sought by technology
companies and opposed by big pharmaceutical makers is in deep trouble
in the U.S. Senate, Democratic and Republican aides said on Monday.
Big high-tech companies such as Cisco and Hewlett-Packard began
pushing for reform legislation years ago to cut the number of patent
infringement lawsuits and the amount of damages paid.
A version of the bill passed the House of Representatives last
September but a similar measure is stalled in the Senate amid vocal
opposition from drug maker Eli Lilly & Co, seed and herbicide
company Monsanto Co, and smaller tech companies that fear lower damages
would leave them vulnerable to infringers.
"I wouldn't say the bill is dead, but let's say right now it's on ice," said one Democratic aide.
The measure has drawn opposition mostly from Republicans and lacks
the 60 votes needed in the 100-member Senate to clear a likely
procedural roadblock, aides said.
"We'll try it again next year when we will have more (Senate)
Democrats," said a second Democratic aide. Democrats now control the
Senate with a slim majority but are expected to add seats in the
November elections.
"It's almost dead," said a Republican aide. "But people are still
talking to each other. When they completely stop talking, then it is
dead."
The bill is bogged down in the Senate over how high damages for patent infringement should be and other sticking points.
The Bush administration also opposes the damages portion of the House version of the bill.
Under current law, damages can be calculated as the entire market
value of the product. That number can be tripled when the patent
infringement is found to be intentional or willful.
The tech industry -- which sells devices that can have many patented
elements -- wants to reduce damage awards to deter people, who they
privately call "patent trolls", from filing what tech companies say are
unwarranted lawsuits.
The pharmaceutical industry, whose drugs often have just one or two
patents, says it needs the threat of high damages to protect their
intellectual property.
Under a failed compromise, judges hearing patent cases would have
ruled on whether the patent involved was central to the product or not.
The potential awards paid by an infringer would have been adjusted
accordingly.
Some experts have also questioned whether the patent legislation goes too far.
"The central problem with all of these proposed changes is that they
would inject far too much uncertainty and arbitrariness into the patent
system," says Scott Kieff, who teaches patent law at Washington
University School of Law in St. Louis.
"Most proposed changes would have been terrible, resulting in less
innovation and economic growth and fewer jobs for American workers.
They also would seriously undermine U.S. efforts over the years to
ensure predictable enforcement of intellectual property rights
overseas," Kieff wrote in a e-mail interview.
Other proposals in the legislation were aimed at stopping
forum-shopping, or choosing court venues that are fast or
plaintiff-friendly.
The legislation would have allowed post-grant reviews, or public
comment on patents after they are granted; and changed the punishment
for "inequitable conduct," or failing to inform the patent office of
information relevant to patentability. The punishment now is loss of
the patent.
(Editing by Tim Dobbyn)
© Reuters 2008 All rights reserved